Table 1 Patient population description
Dendritics cell vaccine (n = 8) | Observation (n = 7) | |
|---|---|---|
Age (mean, CI 95%) | 58.75 (52.25–65.25) | 56.29 (52.92–69.66) |
Sex (%) | ||
Male | 50% | 62.5% |
Female | 50% | 37.5% |
ECOG (median, range) | 0 (0–1) | 0 (0–1) |
ESMO (median, range) | 1 (0–1) | 0 (0–1) |
Köhne (median, range) | 0 (0–1) | 0 (0) |
Nagashima score (%) | ||
Low risk | 0% | 50% |
Moderate risk | 33.33% | 50% |
High risk | 66.67% | 0% |
Fong score (%) | ||
Low risk | 50% | 57.14% |
High risk | 50% | 42.86% |
Histology (%) | ||
Adenocarcinoma | 87.5% | 100% |
Mucinous | 12.5% | 0% |
CEA (%) | ||
< 200 ng/ml | 50% | 85.7% |
> 200 ng/ml | 50% | 14.3% |
Metastatic disease at diagnosis | 87.5% | 57.4% |
Neoadjuvant cycles (mean, CI 95%) | 5.75 (4.68–6.82) | 6.57 (5.67–7.47) |
KRAS status | ||
Mutant | 62.5% | 57.14% |
Wild type | 37.5% | 42.6% |
MSI status | 37.5% | 0% |